The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Evaxion to Present AI-Driven Polio Vaccine Concepts in Collaboration with Gates Foundation

Key Facts

1Evaxion developed novel polio vaccine concepts using its AI-Immunology™ platform.

Evaxion A/S (NASDAQ: EVAX) has announced the development of novel polio vaccine concepts utilizing its proprietary AI-Immunology™ platform. The project was conducted in collaboration with the Bill & Melinda Gates Foundation, highlighting a significant partnership in global health innovation. The company is scheduled to present its research findings at the World Vaccine Congress in Washington D.C., taking place from March 31 to April 2, 2026. This presentation aims to demonstrate the efficacy of AI-driven design in addressing complex global health challenges and creating superior vaccine candidates. The validation provided by the Gates Foundation partnership represents a key milestone for Evaxion’s technological approach. Market analysts view this development as a positive indicator for the company's biotech platform and its future growth potential within the NASDAQ-listed biotech sector.